Skip to main content

OncoSil Medical Health Care
Cancer Health Care

$0.012 (0%)

High

$0.01

Low

$0.01

Trades

21

Turnover

$70,215

Volume

5,851,219
30 June 2023 at 4:10pm
Register to track OSL and receive email alerts.

OncoSil Medical Limited, a medical device company, focuses on the development and commercialization of localized radiation therapy for the treatment of pancreatic and distal cholangiocarcinoma in worldwide. Its lead product is OncoSil, a brachytherapy device indicated for the treatment of patients with locally advanced pancreatic cancer in combination with gemcitabine-based chemotherapy. OncoSil Medical Limited was incorporated in 2005 and is headquartered in Macquarie Park, Australia.

Expand Company Description

Market Cap (10-Oct)

$49,193,040 (1,393rd)

Close (30-Jun)

$0.012

Volume (30-Jun)

5,851,219

Shortsold (25-Aug)

59,314 (0.01%) (600th)

52w High

$0.015

52w Low

$0.004

P/E

-

EPS

-0.01
Subject
StockBot
OSL Ann: Multi-Centre Data on OncoSil in Metastatic Pancreatic Cancer

StockBot
OSL Ann: Notification of cessation of securities - OSL

StockBot
OSL Ann: Ethics Committee Approves PANCOSIL Clinical Trial

StockBot
OSL Ann: Change of CFO, Company Secretary and Registered Office

StockBot
OSL Ann: Resignation of Chief Financial Officer

StockBot
OSL Ann: Mr Otto Buttula to Retire from the Board

StockBot
OSL Ann: First patient treatment in Italy

StockBot
OSL Ann: Becoming a substantial holder

StockBot
OSL Ann: Notification of cessation of securities - OSL

StockBot
OSL Ann: Change of Director's Interest Notice - Brian Leedman

StockBot
OSL Ann: Change of Director's Interest Notice - Nigel Lange

StockBot
OSL Ann: Top 20 Holdings and Distribution Schedule of OSLO Options

StockBot
OSL Ann: Application for quotation of securities - OSL

StockBot
OSL Ann: Entitlement Offer Results and Shortfall Notification

StockBot
OSL Ann: First patient enrolled in the TRIPP-FFX Clinical Study

StockBot
OSL Ann: OncoSil to streamline operating structure

StockBot
OSL Ann: First year anniversary of the OSPREY post-marketing registry

StockBot
OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
OSL Ann: Late Lodgement of Change in Director's Interest Notice

StockBot
OSL Ann: Update - Proposed issue of securities - OSL

StockBot
OSL Ann: Oral presentation at The Mayo Clinic IMPACT Course

StockBot
OSL Ann: Further commercial milestones achieved in Spain

StockBot
OSL Ann: Extension of Closing Date of Entitlement Offer

StockBot
OSL Ann: Additional Binding Commitment Received for Entitlement Offer

StockBot
OSL Ann: Letter to Ineligible Shareholders

StockBot
OSL Ann: Entitlement Offer - Despatch of Documents

StockBot
OSL Ann: Non-renounceable Rights Issue Offer Prospectus

StockBot
OSL Ann: Update - Proposed issue of securities - OSL

StockBot
OSL Ann: Commitment received for Offer and updated Timetable

StockBot
OSL Ann: Proposed issue of securities - OSL

StockBot
OSL Ann: Entitlement Offer Presentation

StockBot
OSL Ann: Entitlement Offer to raise up to $9.9 million

StockBot
OSL Ann: Final Director's Interest Notice

StockBot
OSL Ann: Change of Director's Interest Notice

StockBot
OSL Ann: Cancellation of Unlisted Options and Loan Funded Shares

StockBot
OSL Ann: Half-Yearly Report Results

StockBot
OSL Ann: Half Yearly Report and Accounts

StockBot
OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
OSL Ann: Two key treatment centres treat first patients with OncoSil

StockBot
OSL Ann: OncoSil achieves milestone of 10 patients treated in Spain

StockBot
OSL Ann: Distribution agreement signed for selected Chinese markets

StockBot
OSL Ann: Change of Director's Interest Notice

StockBot
OSL Ann: Application for quotation of securities - OSL

StockBot
OSL Ann: Cleansing Notice

StockBot
OSL Ann: OncoSil to present at TechKnow Invest 2022

StockBot
OSL Ann: Change of Director's Interest Notice

StockBot
OSL Ann: Quarterly Activities/Appendix 4C Cash Flow Report

StockBot
OSL Ann: Change of Registry Address

StockBot
OSL Ann: OncoSil to present at AusBioInvest 2022

StockBot
OSL Ann: Change of Director's Interest Notice - Nigel Lange

Register to track OSL and receive email alerts.

Similar Companies

AnteoTech
ADO
BPH Energy
BPH
Cryosite
CTE
Genetic Signatures
GSS
Genetic Technologies
GTG
Memphasys
MEM
Palla Pharma
PAL
Proteomics International Laboratories
PIQ